Every plan to build an insurance company starts with the same question: which product first. The wrong instinct is to pick the largest premium pool, because a large pool is large partly because it is well served. The right instinct is to pick the product where your specific advantages matter most, where the risk can be assessed from a short conversation, and where you have personally sat across from the customer. For us that is final expense, and this is the reasoning, including the part where it could be wrong.
What a wedge product has to do
A wedge is not a niche you intend to stay in. It is the entry point that proves the machine works, and it has four jobs. It has to be something people actually want, so demand generation is a matter of reaching them rather than convincing them. It has to carry risk that can be assessed without a medical exam and a six-week file, or the operational advantage disappears into underwriting cost. It has to be a product your own people understand from the selling side, so the first thousand cases are not also your education. And it has to lead somewhere, because a wedge that opens no door is just a small business.
The short version
- The need is real and unprompted. People come looking for burial coverage because they have watched a family handle a funeral without it.
- The risk profile is manageable: modest face amounts, a legible set of health questions, and a small number of factors that do most of the work.
- Our founders sold this product before they built software for it, so the design intent comes from the kitchen table rather than from a market report.
- Simplified issue underwriting can genuinely decide inside one conversation, which is the difference between a sale and a follow-up that never happens.
- It would be the wrong wedge if the risk selection were sloppy, if the distribution were rented, or if persistency were treated as somebody else's report.
The need is real, and it arrives unprompted
Most insurance has to be sold. Final expense is closer to being bought. The people who ask about it are usually reacting to something specific: a sibling who died and left a funeral bill that landed on whoever answered the phone first, or a realization that a spouse would have to make decisions in the worst week of their life while also finding several thousand dollars.
That changes the economics of the top of the funnel in a way that is easy to underrate. When demand is intent-driven, a marketing company is capturing a question someone was already asking rather than manufacturing interest. The conversation an agent has is about whether this is the right amount and the right structure, not about whether the problem exists. Shorter conversations, fewer dead ends, and a customer who is not being talked into something are all downstream of that one fact.
It also means the product can be honest about what it is. Final expense is not a wealth transfer instrument and it should not be sold as one. It covers burial and end-of-life costs, with level premiums and no paperwork marathon. That narrowness is a feature, because a product that promises one legible thing is much harder to mis-sell than one that promises several.
The risk profile is legible
The reason simplified issue works at all in this market is that the face amounts are modest relative to the information you can gather in a conversation. Underwriting is always a question of how much uncertainty you are willing to price for a given amount of exposure. At the coverage sizes this product is designed around, a short set of health questions, prescription history, and the ordinary demographic factors carry most of the predictive weight. The marginal value of a paramedical exam and an attending physician statement is real but small, and the cost of collecting them is not.
That is a very different situation from fully underwritten life at large face amounts, where the exposure justifies a long file and the process cost is a rational expense. It is also different from Medicare Advantage, where the risk is not yours at all and the game is a distribution and compliance game rather than an underwriting one.
Two consequences follow. First, a well-built model can reach a decision from information a person can supply in one sitting, which is what makes a single-session experience possible. Second, disciplined declining is affordable, because the cost of evaluating a case is small enough that turning one away is not throwing away an expensive file. Selective underwriting is only a strategy when evaluation is cheap; otherwise it is a slow way to lose money. That is the link back to owning acquisition.
A product our own people have sold
Dustin Snider and Abri White came out of operating insurance sales rather than out of software. They have sat in living rooms with this product, handled the objections, and watched what happens when an application stalls for three weeks and the applicant stops answering the phone. Every platform in the group exists because one of those experiences was intolerable enough to fix.
This matters more for a wedge than for a later product, because the wedge is where you have no data of your own and have to rely on judgment. Knowing what a good case looks like, which objections are real and which are a polite exit, and which part of the process loses people is knowledge that does not appear in a spreadsheet and cannot be hired quickly. Starting with the product your founders know is a way of borrowing against experience you already have.
Real need
Intent-driven demand from people who have watched a family handle an unfunded funeral. The conversation starts past the question of whether the problem is real.
Legible risk
Modest exposure relative to what a short conversation reveals, so evaluation is cheap enough that declining the wrong case is affordable.
Known product
Sold by our own founders before it was software. The design intent comes from the objections, not from a category analysis.
One session, decided
The operational prize in this product is finishing the conversation you started. In a traditional flow an agent takes an application, submits it, and waits. Requirements come back. The applicant is asked for something they have to find. Days pass, the urgency that prompted the call fades, and a meaningful share of cases simply evaporate, not because anyone declined them but because the process outlasted the intent.
Simplified issue underwriting on a legible risk can be built to decide inside the session. The applicant answers questions, the model evaluates, and the outcome is known before the conversation ends. Note the careful phrasing: this is the design intent for a product in development, not a published decision time, and we are not going to put a number on it before there is an approved product and a real book behind it.
Even the declines get better. In a sequential world a decline is the end of a conversation. When a case has been evaluated against many carriers and products at once, a decline is a routing event, because the next option is already known rather than needing to be researched. That is the subject of comparative underwriting, explained, and it is the mechanism that turns a lost case into a placed one.
Where the wedge leads
A wedge that opens no door is not a wedge. Final expense sits in the senior market, next to Medicare, which the group already serves through lead programs, the dialer, and contracting. The same client record, the same fact-find, the same compliance posture, and the same contracted producers extend to additional life lines and ancillary products without a second platform.
Expansion, then, is adding lines and states to a chain that already works rather than adding vendors. It is also sequential by regulation: product approvals happen state by state, and the plan is built around that rather than around a nationwide launch date. Being patient on the product is not modesty, it is the only available schedule.
Final expense
The wedge product, with simplified issue whole life first
Patented
Comparative underwriting method at the core of risk selection
2
Platforms already in production underneath it
The product company is in development, pending state approval. The layers it will sit on top of are not. See what is live today.
What would make it the wrong wedge
A thesis you cannot falsify is not a thesis. Four things would make this the wrong choice, and three of them are about us rather than about the market.
If the declines are not disciplined
A proprietary book only works if you are willing to turn business away. The pressure runs the other way: a field force wants to place cases, a growth plan wants volume, and a selective model is the thing standing between them and both. If we write the cases we said we would decline, the risk pool stops being the thing that makes the pricing possible, and we will have built an expensive way to sell an ordinary product.
If persistency is treated as somebody else's report
A book that lapses is worse than a book that never wrote, because you paid acquisition and issue costs for nothing and you damaged the customer relationship on the way. Final expense is a product where persistency is sensitive to how the sale was made. If the feedback from lapse behavior does not reach the program and filter level of acquisition quickly, the wedge becomes a treadmill.
If the distribution is rented after all
Owning contracting is what makes the field force something other than a channel. If we end up depending on producers whose relationship is with someone else, then the product is being placed by people whose incentives we do not control, and the honest pricing argument weakens considerably.
If regulatory timelines outrun the plan
This one is not under our control. Product approvals are sequential and slow, and a plan that requires them to be fast is a plan that fails on a calendar rather than on a spreadsheet. The mitigation is that the technology companies have their own customers and their own revenue, so the group is not holding its breath waiting on a filing.
The narrow claim
We are not claiming final expense is the biggest opportunity in insurance. We are claiming it is the product where a vertically integrated group with owned demand, cheap evaluation, and its own distribution has the clearest advantage, and where our own judgment is worth the most. Starting narrow means the underwriting model gets validated on a book we understand before additional lines are added, which is a slower path to a larger business and a much shorter path to knowing whether the thesis is true.
If you want the rest of the argument, the strategy page covers the four operating pillars and technology covers the underwriting method. If you are an agent who sells this product and thinks we have something wrong, tell us. That is the most useful message we get.